Castrén S, Mäkelä N, Haikola J, et al. - An 8-week, open-label, uncontrolled pilot study was conducted with 20 problem gamblers (nine men), to evaluate the feasibility of using intranasal naloxone spray to treat gambling disorder (GD). Patients were randomized into group A (n = 10) that took one dose into one nostril (2 mg naloxone), as required, with a maximum of 4 doses/day (max. 8 mg/day) and group B (n = 10) that took one dose into each nostril (4 mg naloxone) as necessitated, with a maximum of 4 doses/day (max 16 mg/day). They found high acceptability and feasibility scores. In group B vs group A, intranasal naloxone use was more prevalent, and so, more naloxone was used. No serious adverse events were listed. The postintervention South Oaks Gambling Screen scores were lower vs preintervention scores. During the trial, depressive symptoms decreased. Preliminary results recommend mixed outcomes in terms of gambling behavior (ie, decreased frequency but not expenditure) with reduced depressive symptoms.